Literature DB >> 1452920

Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era.

J R Bengtson1, A J Kaplan, K S Pieper, N M Wildermann, D B Mark, D B Pryor, H R Phillips, R M Califf.   

Abstract

OBJECTIVES: The purpose of this study is to describe the outcome in cardiogenic shock treated with aggressive reperfusion therapy and to identify factors predictive of in-hospital and long-term mortality.
BACKGROUND: Cardiogenic shock is the most common cause of death in patients admitted to the coronary care unit. Although studies have reported lower mortality rates in shock treated with angioplasty, few studies have described a cohort of patients with shock who were not selected because they were most likely to benefit from reperfusion therapy.
METHODS: A consecutive series of 200 patients admitted with acute myocardial infarction complicated by cardiogenic shock were studied.
RESULTS: The in-hospital mortality rate was 53%. Variables with significant univariable association with in-hospital death included patency of the infarct-related artery, patient age, lowest cardiac index, highest arteriovenous oxygen difference and left main coronary artery disease. The most important independent predictors of in-hospital death were patency of the infarct-related artery, cardiac index and peak creatine kinase, MB fraction. The mortality rate in patients with patent infarct-related arteries was 33% versus 75% in those with closed arteries and 84% in those in whom arterial patency was unknown. Patients who survived to hospital discharge were followed up for a median of 2 years, with a mortality rate of 18% after 1 year. The best descriptors of the relation between these variables and postdischarge mortality included age, peak creatine kinase, ejection fraction and patency of the infarct-related artery.
CONCLUSIONS: In a large consecutive series of patients with cardiogenic shock with complete follow-up, patency of the infarct-related artery was most strongly associated with in-hospital and long-term mortality. This finding supports an aggressive interventional strategy in patients with cardiogenic shock.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452920     DOI: 10.1016/0735-1097(92)90440-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

Review 1.  Management of cardiogenic shock complicating acute myocardial infarction: towards evidence based medical practice.

Authors:  S G Williams; D J Wright; L B Tan
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

2.  The Cardiac Surgeon's Perspective on Lethal Myocardial "Reperfusion Injury"

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

3.  Succesful Identification and Management of High-Risk Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

4.  Cardiogenic Shock.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

5.  Evaluation of coronary artery bypass grafting in acute myocardial infarction.

Authors:  Hideyuki Fumoto; Ryuzo Sakata; Yoshihiro Nakayama; Yoshio Arai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-08

6.  Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 7.  Management of acute myocardial infarction in the elderly.

Authors:  D E Forman; M W Rich
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 8.  Cellular responses to mild heat stress.

Authors:  H G Park; S I Han; S Y Oh; H S Kang
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

Review 9.  Heart failure and shock complicating acute coronary syndromes.

Authors:  Frederick A Spencer; Theo Meyer
Journal:  Curr Cardiol Rep       Date:  2005-07       Impact factor: 2.931

Review 10.  [Infarct-related cardiogenic shock : Prognosis and treatment].

Authors:  R Prondzinsky; H Lemm; A Geppert; M Buerke; M Russ; K Werdan
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-02       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.